Viking Therapeutics Inc [VKTX] stock is trading at $28.17, up 3.99%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VKTX shares have gain 7.19% over the last week, with a monthly amount glided 3.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Viking Therapeutics Inc [NASDAQ: VKTX] stock has seen the most recent analyst activity on April 29, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $104. Previously, Goldman started tracking the stock with Neutral rating on April 08, 2025, and set its price target to $30. On February 13, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $102 on the stock. Citigroup started tracking the stock assigning a Neutral rating and suggested a price target of $38 on February 07, 2025. Piper Sandler initiated its recommendation with a Overweight. B. Riley Securities started tracking with a Buy rating for this stock on November 22, 2024, and assigned it a price target of $109. In a note dated November 04, 2024, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $90 to $102.
Viking Therapeutics Inc [VKTX] stock has fluctuated between $18.92 and $81.73 over the past year. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Viking Therapeutics Inc [NASDAQ: VKTX] shares were valued at $28.17 at the most recent close of the market. An investor can expect a potential return of 166.24% based on the average VKTX price forecast.
Analyzing the VKTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.14 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.26 points at the first support level, and at 26.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.96, and for the 2nd resistance point, it is at 29.76.
Ratios To Look Out For
For context, Viking Therapeutics Inc’s Current Ratio is 44.25. Further, the Quick Ratio stands at 44.25, while the Cash Ratio is 1.94.
Transactions by insiders
Recent insider trading involved Rouan Sarah Kathryn, Director, that happened on Mar 31 ’25 when 1240.0 shares were purchased. President & CEO, Lian Brian completed a deal on Jan 06 ’25 to sell 0.19 million shares. Meanwhile, Chief Operating Officer Mancini Marianna sold 54215.0 shares on Jan 06 ’25.
